NEWS
News Updates
A seminar on a clinical study protocol for non-small cell lung cancer was successfully held.
Release time:
2021-01-05 17:00
Source:
During the period of regularized epidemic prevention and control, faced with numerous challenges on the clinical research journey, our company has continuously explored new ideas, new approaches, and new models. In response to the national call and while ensuring epidemic prevention and safety, we have ensured that all ongoing clinical projects are progressing smoothly and steadily.
2020 On December 23, our company, in collaboration with the sponsor and experts from departments including respiratory medicine, oncology, data science, and statistics, successfully held a virtual conference—the “Discussion Meeting on the Clinical Study Protocol for Non-Small Cell Lung Cancer.”
This study employs a multicenter, randomized, double-blind, placebo-controlled parallel-group design. Evaluation Product Efficacy and Safety of Combination Chemotherapy for Non-Small Cell Lung Cancer, Project Led by Director Wang Mengzhao from Peking Union Medical College Hospital, the initiative involves the joint participation of 20 institutions, including Hunan Provincial Tumor Hospital, the First Affiliated Hospital of Bengbu Medical College, and the Third People’s Hospital of Zhengzhou. Experts attending the meeting engaged in professional and enthusiastic discussions on various aspects, including study design, key indicators, clinical procedures, subject protection, and potential benefits. They reached consensus on each issue, and the conference was a complete success!
We would like to thank all the leaders and professors for their strong support and active participation.
Eurasia Huizhi is a Contract Research Organization (CRO) specializing in providing Phase I to IV clinical studies and related technical services for new drug development. The company places great emphasis on building a strong reputation, grounding its work in real medical needs, and leveraging cutting-edge theoretical foundations. With over 500 pharmaceutical project experiences under its belt, the company’s core team boasts more than 10 years of industry experience each. Guided by an ethos of integrity, mutual win-win cooperation, diligence, and professionalism, Eurasia Huizhi is committed to becoming a leader in pharmaceutical MA solutions. Together with pharmaceutical companies, we strive to bring patients hope for recovery in less time and at lower costs.
Recommended Services
2020-09-25
Eurasia Huizhi boasts more than ten Phase I strategic collaboration centers, providing high-quality, specialized resources for early-phase clinical studies of innovative drugs. For each project, our expert medical team drafts initial clinical study protocols, consults with clinical experts in relevant fields, and develops clinically feasible and regulatory-compliant implementation plans. The company has extensive experience in conducting clinical trials for a variety of new drugs, including chemical drugs, traditional Chinese medicines, and biologics. Our services include: 1) Feasibility Assessment: Clinical trial feasibility evaluation, identification of centers/researchers, and center feasibility assessment & qualification review. 2) Medical and Clinical Strategy & Planning: Clinical trial planning & execution, risk identification & management.
2020-09-25
Opinions of the General Office of the State Council on Conducting Evaluations of the Quality and Efficacy Consistency of Generic Drugs (Guobanfa [2016] No. 8) Generic drugs that were approved for marketing prior to the implementation of the new classification system for chemical drug registration—and which have not been approved in accordance with the principle of consistency in quality and efficacy with the originator drugs—must undergo consistency evaluations. The consistency evaluation of generic drugs refers to the phased and batch-wise assessment of the quality consistency of generic drugs already approved for marketing, based on the principle of consistency in quality and efficacy with the originator drugs. In other words, generic drugs must achieve a level of quality and efficacy that is consistent with the originator drugs. The purpose of conducting these consistency evaluations is to ensure that generic drugs are comparable to the originator drugs in terms of both quality and efficacy.
Leave a message for inquiry
Follow us
Address: Room 3008, Building I, Yingkun Century, No. 6 Courtyard, East Road of the Automobile Museum, Fengtai District, Beijing
Phone: +86 10 86229816 Fax: 010-83739030
Email: bd-oyhz@healtech.com.cn (Business Cooperation)
ouyahuizhi-hr@healtech.com.cn (Resume Submission)
Follow the official account
WeChat Official Account
Friendship Links:Beijing Aotekang Pharmaceutical Technology Development Co., Ltd. Suzhou Suhao Biomaterials Technology Co., Ltd. Beijing Dikang Pharmaceutical Investment Management Co., Ltd. Center for Drug Evaluation, National Medical Products Administration National Medical Products Administration
Copyright © Eurasia Huizhi (Beijing) Medical Research Co., Ltd.